Everything below concerns Tesamorelin. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-09-08. Numbers and descriptions here follow the published literature rather than marketing material.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH receptor agonist |
| Residue count | 44 amino acids | Matches human GHRH(1-44) length |
| N-terminal modification | trans-3-hexenoyl group | Confers resistance to dipeptidyl peptidase IV |
| Appearance | White to off-white powder | Typically supplied lyophilized in a sealed vial |
| Solubility class | Freely soluble in water | Hydrophilic peptide; polar solvent compatible |
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Gaddafi described his approach to economics as "Islamic socialism". For him, a socialist society could be defined as one in which men controlled their own needs, either through personal ownership or through a collective. Although the early policies pursued by his government were state capitalist in orientation, by 1978 he believed that private ownership of the means of production was exploitative and thus he sought to move Libya away from capitalism and towards socialism. Private enterprise was largely eliminated in favour of a centrally controlled economy. The extent to which Libya became socialist under Gaddafi is disputed. Bearman suggested that while Libya did undergo "a profound social revolution", he did not think that "a socialist society" was established in Libya. Conversely, St. John expressed the view that "if socialism is defined as a redistribution of wealth and resources, a socialist revolution clearly occurred in Libya" under Gaddafi's regime. Gaddafi was staunchly anti-Marxist, and in 1973 declared that "it is the duty of every Muslim to combat" Marxism because it promotes atheism. In his view, ideologies like Marxism and Zionism were alien to the Islamic world and were a threat to the ummah, or global Islamic community. Nevertheless, Blundy and Lycett noted that Gaddafi's socialism had a "curiously Marxist undertone", with political scientist Sami Hajjar arguing that Gaddafi's model of socialism offered a simplification of Karl Marx and Friedrich Engels's theories.
==== Electroporation ==== Electroporation is a method that uses high voltage to create pores in the membranes of mammalian cells. By pulsing with electricity, local areas of the cell membrane transiently destabilize and DNA can then enter the cell. At appropriate field strengths, damage to the host cell in minimal. This technique can be used for both short-term and long-term transfectants. It is also effective with almost any tissue type and has displayed high levels of gene delivery with an increase in the distribution of cells expressing the DNA.
Numerous analogues and derivatives of DMT are known. Some examples include tryptamine (T), N-methyltryptamine (NMT), serotonin (5-hydroxytryptamine; 5-HT), psilocin (4-HO-DMT), psilocybin (4-PO-DMT), 4-AcO-DMT (psilacetin), 4-PrO-DMT, bufotenin (5-HO-DMT or N,N-dimethylserotonin), and 5-MeO-DMT (mebufotenin; N,N,O-trimethylserotonin). Some further examples include methylethyltryptamine (MET), diethyltryptamine (DET), methylpropyltryptamine (MPT), dipropyltryptamine (DPT), methylisopropyltryptamine (MiPT), diisopropyltryptamine (DiPT), methylallyltryptamine (MALT), diallyltryptamine (DALT), and pyr-T (N,N-tetramethylenetryptamine) and their derivatives. Some lesser-known DMT derivatives include 1-methyl-DMT, lespedamine (1-MeO-DMT), 2-methyl-DMT, 4-methyl-DMT, 4-MeO-DMT, 4-fluoro-DMT, 5-methyl-DMT, 5-ethyl-DMT, 5-TFM-DMT, 5-EtO-DMT, 5-TFMO-DMT, 5-fluoro-DMT, 5-chloro-DMT, 5-bromo-DMT, 6-fluoro-DMT, 5,6-dibromo-DMT, 4,5-MDO-DMT, 4,5-DHP-DMT, 5,6-MDO-DMT, 5-MeS-DMT, 6-methyl-DMT, 6-HO-DMT, 6-MeO-DMT, 7-methyl-DMT, 7-MeO-DMT, NBoc-DMT (NB-DMT), α,N,N-TMT (α-Me-DMT), and α,N,N,O-TeMS (5-MeO-α-Me-DMT). Cyclized tryptamines containing DMT in their chemical structures include ibogalogs like ibogainalog and tabernanthalog; iboga alkaloids like ibogaine and noribogaine; lysergamides like ergine (LSA) and lysergic acid diethylamide (LSD); and partial ergolines and lysergamides like N-DEAOP-NMT, 10,11-seco-LSD, RU-28306 (4,α-methylene-DMT), RU-28251 (4,α-methylene-DPT), Bay R 1531 (LY-197206; 4,α-methylene-5-MeO-DPT), and NDTDI (8,10-seco-LSD), among others.
Sources: en.wikipedia.org
Biphalin is a dimeric enkephalin endogenous peptide (Tyr-D-Ala-Gly-Phe-NH)2 composed of two tetrapeptides derived from enkephalins, connected 'tail-to-tail' by a hydrazide bridge. The presence of two distinct pharmacophores confers on biphalin a high affinity for both μ and δ opioid receptors (with an EC50 of about 1–5 nM for both μ and δ receptors), therefore it has analgesic activity. Biphalin presents a considerable antinociceptive profile. In fact, when administered intracerebroventricularly in mice, biphalin displays a potency almost 7-fold greater than that of the ultra-potent alkaloid agonist, etorphine and 7000-fold greater than morphine; biphalin and morphine were found to be equipotent after intraperitoneal administration. The extraordinary in vivo potency shown by this compound is coupled with low side-effects, in particular, to produce no dependency in chronic use. For these reasons, several efforts have been carried out in order to obtain more information about structure-activity relationship (SAR). Results clearly indicate that, at least for μ receptor binding, the presence of two pharmacophores is not necessary; Tyr1 is indispensable for analgesic activity, while replacing Phe at the position 4 and 4' with non-aromatic, but lipophilic amino acids does not greatly change the binding properties and in general 4,4' positions are found to be important to design biphalin analogues with increased potency and modified μ/δ selectivity.
== Distribution and habitat == Psilocybe cubensis is a pan-tropical species, occurring in the Gulf Coast states and southeastern United States, Mexico, in the Central American countries of Belize, Costa Rica, Panamá, El Salvador and Guatemala, the Caribbean countries Cuba, the Dominican Republic, Puerto Rico, Guadalupe, Martinique, and Trinidad, in the South American countries of Argentina, Bolivia, Brazil, Colombia, French Guiana, Paraguay, Uruguay and Peru, Southeast Asia, including Thailand, Vietnam, Cambodia and Malaysia, India, Australia, Fiji, and possibly Nepal and Hawaii. Psilocybe cubensis is found on cow (and occasionally horse) dung, sugar cane mulch or rich pasture soil, with mushrooms appearing from February to December in the northern hemisphere, and November to April in the southern hemisphere. In Asia, the species grows on water buffalo dung. Along with other fungi that grow on cow dung, P. cubensis is thought to have colonized Australia with the introduction of cattle there, 1800 of which were on the Australian mainland by 1803—having been transported there from the Cape of Good Hope, Kolkata and the American west coast. In Australia, the species grows between northern Queensland to southern New South Wales. In March 2018, several Psilocybe cubensis specimens were collected in Zimbabwe in the Wedza District of Mashonaland East province, approx. 120 km southeast of Harare. This was the first reported occurrence of a psilocybin mushroom in Zimbabwe.
Todd Lynn Helton (born August 20, 1973) is an American former professional baseball first baseman who played his entire 17-year Major League Baseball (MLB) career for the Colorado Rockies. A five-time All-Star, four-time Silver Slugger, and three-time Gold Glove Award winner, Helton holds the Rockies' club records for hits (2,519), home runs (369), doubles (592), walks (1,335), runs scored (1,401), runs batted in (RBIs, with 1,406), games played (2,247), and total bases (4,292), among others. Helton grew up in Tennessee and played college baseball and football for the Tennessee Volunteers. The Rockies drafted him in the first round of the 1995 MLB draft, and he debuted in the majors in 1997. During his peak from 1999 to 2004, Helton met or topped these benchmarks each season: .320 batting average, 39 doubles, 30 home runs, 107 runs scored, 96 RBI, .577 slugging percentage and .981 on-base plus slugging. In 2000, he won the batting title with a .372 average and also led MLB with a .698 slugging percentage, 59 doubles, and 147 RBI and the National League (NL) with 216 hits. Helton helped the Rockies win the NL pennant in 2007 before being swept in the World Series. He collected his 2,000th career hit in May 19, 2009 and his 2,500th on September 1, 2013. He retired at the end of that season, homering in his final game at Coors Field. Helton was inducted into the Baseball Hall of Fame in 2024, his sixth year on the ballot.
Sources: en.wikipedia.org
The principal difference is a chemical cap on the N-terminal tyrosine that prevents rapid enzymatic cleavage. Native GHRH is degraded within minutes in plasma, whereas the modified peptide persists considerably longer. The amino acid backbone otherwise mirrors the natural hormone.
No. It is a receptor agonist that stimulates the pituitary to release endogenous growth hormone. It does not contain or deliver growth hormone. Its downstream effects therefore depend on a functioning pituitary and an intact signaling pathway.
Pituitary responsiveness, receptor availability, and the natural pulsatility of the growth hormone axis all contribute. Because the compound amplifies an existing release pattern rather than overriding it, timing and physiological state matter. Individual variability in response is well documented but not fully explained.
It mirrors the 44-residue form of human growth hormone-releasing hormone. A hexenoyl group on the N-terminal tyrosine distinguishes it from the unmodified hormone. The change is intended to improve resistance to enzymatic breakdown.